MSH2

Across TCGA pan-cancer cohorts, MSH2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MSH2 data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MSH2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MSH2 expression acts as an unfavorable survival marker, although some lineages such as LSCC and PDAC show a favorable association.

CCRCC, LSCC, and HNSC are the cancer types where MSH2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	0.764	0.973	.001	32	view →
LSCC	OS	Tertile	II,III,IV	0.945	0.517	.004	10	view →
HNSC	OS	Tertile	All	0.581	0.844	.004	9	view →
PDAC	DFS	Median	IV	0.934	0.250	.024	6	view →
LUAD	OS	Quartile	All	0.720	1.000	.034	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MSH2–CCRCC (DFS)

Open the CCRCC breakdown →